News

Inhibikase Receives Orphan-Drug Designation for risvodetinib in Multiple System Atrophy

1 Mins read

Shares of Inhibikase Therapeutics surged in premarket trading on Wednesday following the company’s recent acquisition of orphan-drug designation from the U.S. Food and Drug Administration (FDA) for its flagship program, risvodetinib. This medical breakthrough is specifically aimed at treating multiple system atrophy (MSA), a rare and incurable neurological disease known for its degenerative effect on certain brain regions.

At present, there are no FDA-approved therapeutic interventions available to address the symptoms or modify the progression of MSA. The orphan-drug program by the FDA grants special recognition to drugs and biologics designed to tackle diseases and disorders that impact fewer than 200,000 individuals in the United States. Moreover, this designation provides the drugs with an extended period of marketing exclusivity, protecting them against potential competitors.

Inhibikase Therapeutics is currently focused on advancing its animal-model studies to explore the therapeutic potential of risvodetinib in blocking the progression of MSA as well as potentially reversing functional loss associated with this debilitating neurological condition.

The shares of Inhibikase skyrocketed by 22% in premarket trading, reaching $1.71 per share from their previous closing price of $1.40.

Related posts
News

15 ransomware gangs 'go dark' to enjoy 'golden parachutes'

4 Mins read
PLUS: China’s Great Firewall springs a leak; FBI issues rare ‘Flash Alert’ of Salesforce attacks; $10m bounty for alleged Russian hacker; and…
News

Bitcoin Price Prediction: Where Is BTC Price Heading In September; Could New All-Time Highs Be Hit

1 Mins read
The month of September is shaping up to be a crucial period for Bitcoin (BTC) as the world’s largest cryptocurrency faces mixed…
News

Ethereum's Rally to $6,000+ Is About to Get the Next Boost

1 Mins read
Fast forward, the red W-iii peaked at $4792 (the 176.4% extension). Ether then dropped to $4067 for the red W-iv (the 123.6%…

Leave a Reply

Your email address will not be published. Required fields are marked *

9 + 1 =